Interventions for chronic palmoplantar pustulosis

Obeid, Grace; Do, Giao; Katsahian, Sandrine; Kirby, Lisa; Hughes, Carolyn; Cleach, Laurence Le

doi:10.1002/14651858.cd011628

Cited by 5 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 Meta-analysis about interventions for chronic PPP included people with PPP or PPPP. 9 Regarding conventional systemic treatments, evidence is lacking for major treatments such as acitretin, methotrexate and cyclosporin. Concerning biologic therapy, secukinumab and guselkumab are probably superior to placebo in reducing severity.…”

Section: Discussionmentioning

confidence: 99%

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Marovt

Marko

2021

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none is accepted as being effective in general. Apremilast is a small molecule inhibitor of phosphodiesterase 4 approved for the treatment of plaque psoriasis and psoriatic arthritis. We report three cases of palmoplantar pustulosis treated with apremilast monotherapy. Our three cases, as well as previous reports, demonstrate the potential for apremilast to be beneficial for a subset of patients with palmoplantar pustulosis or palmoplantar pustular psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Marovt

Marko

2021

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…These studies have shown improvement in PPP skin lesions after tonsillectomy (Takahara, 2011), leading to this procedure being a common treatment for PPP in Japan (Kobayashi et al, 2020). Of note, a recent Cochrane review noted that most interventions for PPP do not have high-quality evidence supporting their use but did not specifically analyze tonsillectomy (Obeid et al, 2020).…”

Section: Discussion Of Incorrect Answersmentioning

confidence: 99%

SnapshotDx Quiz: May 2021

Raval

Dube

Musiek

2021

Journal of Investigative Dermatology

View full text Add to dashboard Cite

“…According to the Cochrane process, a protocol was reviewed and published in the Cochrane Library, 11 and in PROSPERO (CRD42015026183).…”

Section: Methodsmentioning

confidence: 99%

“…We searched 13 electronic databases and trial registers up to July 2020 (Table S1; see Supporting Information). 10 Search equations are presented in Appendices S1-S5 (see Supporting Information). The bibliographies of the included studies were also searched for further references to relevant trials.…”

Section: Search Strategymentioning

confidence: 99%

See 1 more Smart Citation

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments

Obeid¹,

Kirby

et al. 2020

Br J Dermatol

View full text Add to dashboard Cite

Summary Background Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles. Objectives To assess the effects of interventions for chronic PPP to induce and maintain complete remission. Methods We searched for randomized controlled trials (RCTs), including people with PPP or chronic palmoplantar pustular psoriasis, in the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS and eight trials registers up to July 2020. Study selection, data extraction and risk‐of‐bias assessment were carried out independently by two review authors. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. Results We included 37 RCTs (1663 participants, 76% women, mean age 50 years). Mean treatment duration was 11 weeks. Topical vitamin D derivative may be more effective than placebo in achieving clearance [risk ratio (RR) 7·83, 95% confidence interval (CI) 1·85–33·12; low‐certainty evidence from two trials]. Concerning biological therapies, there was little or no difference between etanercept and placebo in achieving clearance (low‐certainty evidence from one trial), ustekinumab is less effective than placebo in reducing severity (low‐certainty evidence from one trial), and guselkumab (RR 2·88, 95% CI 1·24–6·69) and secukinumab (RR 1·55, 95% CI 1·02–2·35) are probably better in reducing disease severity (moderate‐certainty evidence from two and one trial(s), respectively) but may cause more serious adverse events than placebo. Conclusions Evidence is lacking for or against major chronic PPP treatments. Risk of bias and imprecision limit our confidence in the results.

show abstract

Interventions for chronic palmoplantar pustulosis

Abstract: Interventions for chronic palmoplantar pustulosis (Review)

Cited by 5 publications

References 47 publications

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

SnapshotDx Quiz: May 2021

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments

Contact Info

Product

Resources

About